Profile data is unavailable for this security.
About the company
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. It operates through four divisions: Generics API, Generics FDF, Laurus Synthesis, and Laurus Bio. The Generics API is a third-party API supplier for antiretrovirals. The Generic FDF business focuses on oral solid formulations. The Laurus Synthesis provides drug development and manufacturing services to global pharma, crop science, animal health, and others. The Laurus Bio offers comprehensive services from clone and strain engineering to production, supporting clients across the microbial precision fermentation spectrum. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports.
- Revenue in INR (TTM)50.54bn
- Net income in INR1.48bn
- Incorporated2005
- Employees6.01k
- LocationLaurus Labs LtdSerene Chambers, Road No 7, BanjarahillsHYDERABAD 500034IndiaIND
- Phone+91 4 039804333
- Fax+91 4 066594320
- Websitehttp://www.lauruslabs.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wockhardt Ltd | 28.93bn | -3.43bn | 158.40bn | 2.39k | -- | -- | -- | 5.48 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 163.85bn | 1.65k | 48.76 | -- | 41.12 | 10.02 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Sanofi India Ltd | 23.83bn | 4.30bn | 166.05bn | 2.17k | 38.64 | 24.26 | 35.48 | 6.97 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 171.82bn | 940.00 | 179.24 | -- | 154.92 | 12.38 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Eris Lifesciences Ltd | 22.62bn | 3.80bn | 185.98bn | 3.08k | 48.96 | -- | 30.47 | 8.22 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 190.99bn | 995.00 | 34.59 | -- | 20.51 | 2.79 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 219.16bn | 14.86k | 34.80 | -- | 24.21 | 3.48 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Pfizer Ltd | 22.25bn | 6.09bn | 249.64bn | 1.72k | 41.03 | -- | 37.27 | 11.22 | 133.01 | 133.01 | 486.27 | -- | -- | -- | -- | 12,926,610.00 | -- | 14.22 | -- | 17.71 | 65.06 | 61.37 | 27.35 | 24.05 | -- | 43.74 | -- | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Laurus Labs Ltd | 50.54bn | 1.48bn | 251.98bn | 6.01k | 170.39 | -- | 45.59 | 4.99 | 2.74 | 2.74 | 93.40 | -- | -- | -- | -- | 8,413,434.00 | -- | 10.13 | -- | 16.47 | 52.80 | 47.63 | 3.01 | 12.83 | -- | 2.04 | -- | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Natco Pharma Ltd. | 42.21bn | 16.37bn | 265.28bn | 4.02k | 16.21 | -- | 14.54 | 6.28 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | 14.87 |
| Concord Biotech Ltd | 10.38bn | 3.13bn | 272.12bn | 1.38k | 86.91 | -- | 74.16 | 26.22 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 273.91bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| Piramal Pharma Ltd | 83.73bn | 277.60m | 288.80bn | 6.72k | 1,038.68 | -- | 37.06 | 3.45 | 0.2107 | 0.2107 | 64.75 | -- | -- | -- | -- | 12,462,350.00 | -- | -- | -- | -- | 64.15 | -- | 0.3315 | -- | -- | 7.12 | -- | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 294.67bn | 5.31k | 51.30 | -- | 40.10 | 8.20 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Gland Pharma Ltd | 58.58bn | 7.22bn | 296.63bn | 4.22k | 41.08 | -- | 27.13 | 5.06 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 309.37bn | 1.05k | 128.52 | -- | 104.55 | 33.11 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
Data as of Sep 20 2024. Currency figures normalised to Laurus Labs Ltd's reporting currency: Indian Rupee INR
26.36%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 05 Sep 2024 | 59.21m | 10.98% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 06 Aug 2024 | 15.88m | 2.95% |
| The Vanguard Group, Inc.as of 04 Sep 2024 | 14.61m | 2.71% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2024 | 14.56m | 2.70% |
| SBI Funds Management Ltd.as of 15 Sep 2024 | 13.86m | 2.57% |
| Barclays Wealth Trustees (India) Pvt Ltd.as of 30 Jun 2024 | 6.50m | 1.21% |
| Dimensional Fund Advisors LPas of 05 Sep 2024 | 5.64m | 1.05% |
| BlackRock Fund Advisorsas of 05 Sep 2024 | 4.81m | 0.89% |
| Kotak Mahindra Asset Management Co. Ltd.as of 31 Aug 2024 | 3.60m | 0.67% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Aug 2024 | 3.48m | 0.65% |
More ▼
Data from 30 Jun 2024 - 19 Sep 2024Source: FactSet Research Systems Inc.
